Canguard Health Technologies Inc. announced that, togetherwith its corporate partner Pharmasciences Inc. of Montreal, ithas signed a commercial agreement with Athena NeurosciencesInc. (NASDAQ:ATHN) of South San Francisco, Calif.

Athena will develop and commercialize two unidentifiedCanguard products in the U.S.

Canguard of Vancouver, British Columbia, recently raised aboutC$165,000 (US$129,000) in a private placement to support thecompany's drug development program, which is currentlyfocused on drugs for epilepsy, Parkinson's disease and painrelief.

Moreover, Canguard expects to receive an additional C$600,000(US$469,000) from Ventures West following a Canguardshareholders meeting in mid-February.

(c) 1997 American Health Consultants. All rights reserved.